Chemotherapeutic targeting of myeloid-derived suppressor cells

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Alizadeh, Darya ^a,b   Katsanis, Emmanuel ^a,b   Larmonier, Nicolas ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cancer; Chemoimmunomodulation; Doxorubicin; Helper T lymphocytes; Myeloid derived suppressor cells; ROS

Indexed keywords

DOXORUBICIN; REACTIVE OXYGEN METABOLITE;

ADOPTIVE TRANSFER; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; DRUG CYTOTOXICITY; DRUG MECHANISM; HELPER CELL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; SUPPRESSOR CELL; THYMOMA;

EID: 84899061598     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27359     Document Type: Article

References (10)

1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506.
2. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8:618-31; PMID:18633355; http://dx.doi.org/10.1038/nrc2444.
3. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010; 59:1593-600; PMID:20414655; http://dx.doi. org/10.1007/s00262-010-0855-8.
4. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626.
5. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66:9299-307; PMID:16982775; http://dx.doi.org/10.1158/0008-5472.CAN-06-1690.
6. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16:4583-94; PMID:20702612; http://dx.doi. org/10.1158/1078-0432.CCR-10-0733.
7. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumorbearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713-21; PMID:16166452; http://dx.doi.org/10.1158/1078-0432.CCR-05-0883.
8. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70:3052-61; PMID:20388795; http://dx.doi.org/10.1158/0008-5472.CAN-09-3690.
9. Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T Cell Transfer in Breast Cancer. Cancer Res 2013;Forthcoming; http://dx.doi.org/10.1158/0008-5472.CAN-13-1545; PMID:24197130.
10. Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood 2013; 121:2402-14; PMID:23325835; http://dx.doi.org/10.1182/blood-2012-09-378653.